Bosentan alleviates the pro-fibrotic phenotype of lung scleroderma fibroblasts: Implications for treatment of scleroderma.
主要な著者: | Leask, A, Xu, S, Renzoni, E, Bou-Gharios, G, du Bois, R, Abraham, D, Black, C |
---|---|
フォーマット: | Conference item |
出版事項: |
2005
|
類似資料
-
Bosentan attenuates the profibrotic gene expression profile of lung fibroblasts in scleroderma
著者:: Shiwen, X, 等
出版事項: (2006) -
Effects of bosentan on collagen type I synthesis on in vitro culture of scleroderma skin fibroblasts
著者:: S. Soldano, 等
出版事項: (2011-01-01) -
Successful Treatment with Bosentan of Lower Extremity Ulcers in a Scleroderma Patient
著者:: Alix Naert, 等
出版事項: (2013-01-01) -
CTGF overexpressing mice: a model for human scleroderma
著者:: Sonnylal, S, 等
出版事項: (2006) -
Bosentan Does Not Affect Renal Resistive Index in Scleroderma/Systemic Sclerosis Patients
著者:: Emma Di Poi, 等
出版事項: (2023-11-01)